When a peptide manufacturer advertises an "EDQM approved facility" or a "CEP" for its peptide API, it is making a specific regulatory claim. Here is what that claim actually covers, how the certification works, and what a buyer should verify before treating it as a quality signal.
Source: EDQM Certification of Suitability (CEP) | EDQM CEP Fact Sheet
What "EDQM approved" means
The European Directorate for the Quality of Medicines & HealthCare (EDQM) does not certify facilities the way the FDA registers establishments. What it issues is a Certificate of Suitability (CEP) for a specific substance against a specific European Pharmacopoeia (Ph. Eur.) monograph. The certificate is substance- and site-specific: it confirms that the control of the peptide active substance, as manufactured at a named site, is suitable under the applicable monograph and any additional requirements.
That distinction matters. A CEP is not a blanket "approved facility" badge. It covers the manufacture of particular peptide APIs at particular sites, and it has to be kept current through the EDQM's lifecycle management procedures. Revocations and suspensions are published on the EDQM website.
How a CEP is obtained
Any manufacturer, regardless of geographic origin, can apply to EDQM for a CEP. The process is documented in the fact sheet and the Certification of Suitability procedure:
- Application: The manufacturer submits a dossier covering the synthesis route, starting materials, in-process controls, impurity profile, analytical methods, and stability data.
- Monograph compliance: EDQM assesses whether the substance complies with the relevant Ph. Eur. monograph, including any tests not covered by the monograph that are needed to control quality.
- GMP inspection: Where needed, EDQM or a competent authority inspects the manufacturing site to verify GMP alignment.
- Issue and lifecycle: A CEP is issued in the CEP 2.0 format. The holder must notify EDQM of significant changes and submit variations to keep it valid.
For peptide APIs, this typically means the certificate references a Ph. Eur. monograph for a well-characterized synthetic peptide, such as octreotide, goserelin, leuprolide, desmopressin, or somatostatin. Bachem, for example, publishes the CEPs it holds for peptide APIs like Desmopressin Acetate Ph. Eur., Goserelin Acetate Ph. Eur., and Octreotide Ph. Eur.
Why buyers ask about EDQM approval
The most common reason is market access. A valid CEP is accepted across the EU and by the signatories to the Convention on the Elaboration of a European Pharmacopoeia (currently 39 member states), and is recognized in many markets beyond Europe. It lets a drug product applicant reference the substance's quality without re-submitting the full API dossier in every marketing authorization application. For peptide API suppliers, a CEP is a credible, inspectable quality signal that the product was reviewed against a published standard by a European authority.
What a buyer should verify
If a peptide supplier claims an EDQM-approved facility or a CEP for its peptide API, verify the following rather than taking the claim at face value:
- Certificate number and substance: Ask for the CEP number and confirm the exact peptide API and site named on it. A CEP for one product does not cover other products.
- Search EDQM's database: The EDQM publishes current certificates and status (valid, suspended, revoked) online. Check the number directly.
- Confirm it is current: Certificates can lapse or be varied. Check the revision date and that the holder's current manufacturing site is the one listed.
- Match the site: The manufacturing site on the CEP must be the site actually producing your batch, verified by the batch number and COA.
- Distinguish CEP from GMP: A CEP is substance-specific. It complements, but does not replace, current GMP status for the facility and the finished dosage form.
EDQM-approved status is a meaningful quality signal when verified against the public record. Without that verification, "EDQM approved facility" is a marketing phrase.